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Bisphosphonates are valuable agents for the treatment of
post-menopausal osteoporosis (PMO), hypercalcemia of
malignancy, and osteolytic bone metastases. Oral
bisphosphonates are used mainly to treat PMO and are not
associated with significant nephrotoxicity. In contrast,
nephrotoxicity is a significant potential limiting factor to the
use of intravenous (IV) bisphosphonates, and the
nephrotoxicity is both dose-dependent and infusion
time-dependent. The two main IV bisphosphonates available
to treat hypercalcemia of malignancy and osteolytic bone
disease in the United States are zoledronate and
pamidronate. Patterns of nephrotoxicity described with these
agents include toxic acute tubular necrosis and collapsing
focal segmental glomerulosclerosis, respectively. With both
of these agents, severe nephrotoxicity can be largely avoided
by stringent adherence to guidelines for monitoring serum
creatinine prior to each treatment, temporarily withholding
therapy in the setting of renal insufficiency, and adjusting
doses in patients with pre-existing chronic kidney disease.
In patients with PMO, zoledronate and pamidronate are
associated with significantly less nephrotoxicity, which
undoubtedly relates to the lower doses and longer dosing
intervals employed for this indication. Ibandronate is
approved in the US for treatment of PMO and in Europe for
treatment of PMO and malignancy-associated bone disease.
Available data suggest that ibandronate has a safe renal
profile without evidence of nephrotoxicity, even in patients
with abnormal baseline kidney function.
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The bisphosphonates are a class of antiresorptive agents that
are approved to treat multiple skeletal disorders including
osteoporosis (postmenopausal and steroid-induced), malig-
nancy-associated bone disease, and Paget’s disease of bone.
Bisphosphonates are available as oral and intravenous (i.v.)
preparations. Oral preparations are effective in the treatment
of postmenopausal osteoporosis (PMO) where they are
associated with a significant reduction in fracture risk
predominantly by reducing bone turnover and increasing
bone mineral density. Oral bisphosphonates are generally
considered to be safe and well-tolerated agents.1 Exceptions
include gastrointestinal intolerance, compliance issues, and
contraindications to oral therapy due to underlying disorders
such as achalasia and esophageal strictures.
Higher potency bisphosphonates, which are typically
administered i.v., are effective therapies for malignancy-
related bone disorders (multiple myeloma (MM), metastatic
bone disease, hypercalcemia of malignancy) and Paget’s
disease of bone.2 At lower doses, i.v. bisphosphonates also
may be employed for PMO in patients with gastrointestinal
intolerance or contraindications.1 The use of i.v. bispho-
sphonates for PMO has the benefit of improved compliance
compared to daily oral therapy. Due to the higher doses and
potency, i.v. bisphosphonates have a greater potential for side
effects than oral agents, including multiple forms of
nephrotoxicity, osteonecrosis of the mandible, hypocalcemia,
and postinfusion pyrexia and flu-like symptoms. Reports
have described collapsing focal segmental glomerulosclerosis
(FSGS) and other patterns of glomerular disease in
patients treated with pamidronate. Zoledronate mainly has
been associated with a toxic form of acute tubular necrosis
(ATN).
The focus of this manuscript will be on the i.v. bispho-
sphonates, as these are the predominant forms that are
associated with nephrotoxicity. A brief overview of the
pharmacology and efficacy precedes a more detailed discus-
sion on bisphosphonate nephrotoxicity.
PHARMACOLOGY OF BISPHOSPHONATES
General characteristics
The basic structure of all bisphosphonates is a P–C–P
backbone with R1 and R2 side chains attached at the C
position.3 The composition of the side chains determines the
specific characteristics of the molecule. An OH group at the
R1 position enhances bone affinity, whereas the R2 side chain
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can be either a non-nitrogen moiety or a nitrogen-containing
moiety. Nitrogen-containing side chains (nitrogen-contain-
ing heterocyclic rings and tertiary nitrogen atoms) possess
greater antiresorptive potency. In vitro studies3 demonstrate
an approximately 10,000-fold greater potency of nitrogen-
containing bisphosphonates (pamidronate, zoledronate, and
ibandronate) as compared with non-nitrogen-containing
drugs (etidronate, clodronate).
In the United States, indications for zoledronate include
hypercalcemia of malignancy and MM or bone metastases
from solid tumors (Table 1). For these indications,
zoledronate is administered at a dose of 4 mg i.v. monthly
infused over at least 15 min. Zoledronate is not recommend
for use in patients with a creatinine clearance (CrCl) o30 ml/
min, and the dose should be adjusted for CrCl values between
30–60 cc/min. Indications for pamidronate include hypercal-
cemia of malignancy, osteolytic bone lesions from MM or
breast cancer, and Paget’s disease. For malignant indications,
the recommended dose of pamidronate is up to 90 mg i.v.
monthly infused over 3 h. For both pamidronate and
zoledronate, serum creatinine should be measured prior to
each administration and treatment should be withheld
following a 0.5 mg/dl increase in serum creatinine in patients
with normal renal function, or a 1.0 mg/dl increase in serum
creatinine in patients with abnormal renal function at
baseline. Intermittent evaluation of proteinuria is also
recommended at 3–6 month intervals. Ibandronate is Food
and Drug Administration approved for treatment of PMO
but not malignancy-associated bone disease. The three
approved regimens for PMO are 2.5 mg p.o. daily, 150 mg
p.o. once per month, and 3 mg i.v. at 3-month intervals.
Similar to the other agents, ibandronate is not recommended
for use in patients with a CrCl o30 cc/min.
Outside the United States, i.v. ibandronate is approved by
the European Union for the treatment of PMO and
malignancy-associated bone disease. In general, the European
Commission follows the same guidelines as the Food and
Drug Administration for use of bisphosphonates to treat
these disease states, but permits renal function monitoring to
be utilized based on the clinical assessment of each patient at
the discretion of the physician. Intravenous ibandronate is
employed at 6 mg infused over 15 min for patients with
CrCl 450 cc/min and the infusion time is increased to 1 h for
patients with a CrCl between 30 and 50 cc/min. Although
zoledronate is contraindicated in patients with severe renal
impairment (CrCl o30cc/min), ibandronate can be used
with a dose adjustment (2 mg over 1 h).5
Mechanism of action/pharmacodynamics
Bisphosphonates diminish bone resorption through several
actions. Non-nitrogen-containing drugs primarily inhibit
osteoclast activity by inhibiting ATP-dependent enzymes by
forming nonhydrolyzable analogues of ATP.3 In contrast,
nitrogen-containing bisphosphonates act via extracellular
and intracellular mechanisms. In the extracellular space,
nitrogen-containing bisphosphonates act as calcium chela-
tors, binding to and stabilizing calcium phosphate within
bone matrix and preventing dissolution.3 Second and more
importantly, bisphosphonates exert multiple intracellular
effects within osteoclasts, most notably inhibition of the
mevalonate pathway. The mevalonate pathway is required for
post-translational lipid modification (prenylation) and an-
choring of small GTPases in cell membranes.6 Subcellular
compartmentalization and function of GTPases is critical for
a variety of cellular processes, including integrin signaling,
endosomal trafficking, membrane ruffling, and apoptosis.7–11
Bisphosphonates also are able impair cell energetics through
inhibition of ATP-dependent metabolic pathways12 and to
disrupt the osteoclast cytoskeleton by inhibiting actin
assembly.13
Pharmacokinetics
Intravenous bisphosphonates are distributed between bone
(50% is rapidly incorporated into the bone) and extracellular
fluid.3,14,15 They remain in bone for months to years
depending on the associated bone tissue T1/2 of the
individual bisphosphonate. Once incorporated into bone,
bisphosphonates are metabolically inactive until they are
released by osteoclast activity. The drugs are released from
osteoclasts via transcytosis, re-enter the circulation, and may
later re-accumulate in bone. Negligible amounts of bispho-
sphonates are found in other tissues. Within the serum,
protein binding is variable with ibandronate having the
highest percentage of protein binding (87%), and zoledro-
nate (56%) and pamidronate (54%) having similar but lower
protein binding percentages. The i.v. bisphosphonates are not
metabolized, do not interact with or affect the P450 enzyme
system, and are excreted unchanged by the kidneys by
glomerular filtration, without a significant component of
tubular secretion.3,14,15 As a result, impaired renal function
reduces bisphosphonate excretion and can lead to excessive
serum (and bone) levels with resultant toxicity. In addition to
differences in protein binding, a notable difference between
the bisphosphonates is a longer terminal renal tissue half-life
with zoledronate (150–200 days) as compared with 24 days
for ibandronate.16
Table 1 | Bisphosphonate dosing for malignancy-associated
hypercalcemia or osteolytic disease
Drug Dose/infusion time Interval
Estimated CrCl 460 cc/min
Pamidronate 90 mg over 2–3 h 3–4 weeks
Zoledronate 4 mg over 15 min 3–4 weeks
Estimated CrCl 30 o60 cc/min
Pamidronate 90 mg over 2–3 ha 3–4 weeks
Zoledronate Reduced dosageb 3–4 weeks
Estimated CrCl o30 cc/min
Pamidronate 90 mg over 4–6 ha 3–4 weeks
Zoledronate Not recommended
CrCl, creatinine clearance.
aConsider dose reduction (ASCO 2007; Kyle et al.4).
b3.5 mg (CrCl, 50–60 cc/min); 3.3 mg (CrCl, 40–49 cc/min); 3 mg (CrCl, 30–39 cc/min);
Reference http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf.
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EFFICACY OF BISPHOSPHONATES
Malignant osteolytic bone disease
Intravenous bisphosphonates are effective agents for the
treatment of hypercalcemia of malignancy and malignancy-
associated bone pain. In a phase III double-blind trial enrolling
1648 patients with MM or advanced breast cancer, zoledronate
was shown to have greater efficacy than pamidronate with
respect to reduction in skeletal-related events and event rate for
radiation therapy, with a similar incidence of nephrotoxicity.17
Intravenous bisphosphonates have also been employed less
commonly for nonmalignant conditions such as Paget’s disease
of bone, osteogenesis imperfecta, and Langerhan’s histiocytosis.
Bisphosphonates are an important part of the therapeutic
armamentarium for oncologists as they have been shown to
effectively correct hypercalcemia, reduce osteolytic bone pain,
and perhaps provide anti-tumor effects.
Osteoporosis
There are limited data available on i.v. bisphosphonates for
the treatment of postmenopausal and steroid-induced
osteoporosis. For these indications, substantially lower doses
are employed. Although not approved for treatment of PMO,
a regimen of pamidronate 30–60 mg i.v. at 3-month intervals
has been shown over a 2-year period to increase bone mineral
density of the spine and hip by 11 and 5.5%, respectively,18
with an efficacy similar to oral alendronate.19
Clinical trials have demonstrated that i.v. zoledronate and
ibandronate are effective treatments for PMO which reduce
bone resorption (as measure by biochemical markers) and
increase bone mineral density.20,21 In two trials, i.v. quarterly
ibandronate increased bone mineral density to a similar or
greater degree than oral alendronate and risedronate or
monthly ibandronate,22,23 In a large trial enrolling 7765
women with PMO, once yearly infusion of zoledronate
(5 mg) reduced the risk of vertebral (70%), hip (41%), and
other fractures, increased bone mineral density, and reduced
markers of bone turnover as compared with placebo over a
3-year period.24 Intravenous zoledronate and ibandronate
have also been shown to be effective agents in reducing the
incidence of fracture in patients with recent hip fractures25
and in patients with corticosteroid-induced osteoporosis.26
BISPHOSPHONATE NEPHROTOXICITY
Animal studies
Animal studies have been employed to evaluate the relative
antiresorptive efficacy and nephrotoxicity of the high potency
i.v. bisphosphonates. A single dose of i.v. pamidronate in rats
leads to an increase in urinary malate dehydrogenase, a
sensitive marker of renal injury which can be detected prior
to the development of histopathologic changes.27 When
exposed to higher doses of i.v. pamidronate (5–50 mg/kg),
elevations in serum blood urea nitrogen and creatinine are
seen.28 Mice exposed to greater than 10 mg/kg of pamidro-
nate may exhibit histopathologic changes of kidney injury
including focal cellular necrosis, increased cellular vesicles,
and loss of tubular cell brush border.29
Zoledronate was developed with the goal of finding a
bisphosphonate with maximum potency with respect to
inhibiting bone resorption and minimal nephrotoxicity. A
panel of bisphosphonates was studied in two rat models.27
Zoledronate emerged as having greater antiresorptive capa-
city, similar renal tolerability, and thus a superior therapeutic
ratio than the six available bisphosphonates and five other
novel compounds tested in thyroparathyroidectomized rats.27
Specifically, the therapeutic ratio for zoledronate was 790, as
compared to 40 for Ibandronate and 0.88 for pamidronate.
An important observation in this study was the lack of
correlation between antiresorptive capacity and renal toler-
ability. One-hour infusions of varying doses of zoledronate or
pamidronate were then compared with respect to renal
tolerability. Pamidronate was found to be more nephrotoxic,
requiring 10 mg/kg to increase the serum urea nitrogen by
100% at 4 h, as opposed to 38 mg/kg for zoledronate.27
Other animal studies have suggested that ibandronate may
be safer than zoledronate with respect to nephrotoxicity. A
study in rats comparing the two agents showed that
intermittent dosing of zoledronate (every 3 weeks) induced
more frequent and more severe renal histopathologic injury
than similar doses of ibandronate.30 The difference in
nephrotoxicity was also noted when only a single dose of
each agent was administered. The authors proposed that the
safer renal profile of ibandronate with repetitive dosing might
relate to the shorter renal tissue half-life of ibandronate
(24 days) as compared with zoledronate (150–200 days).31
The same authors went on to administer supratherapeutic i.v.
doses of zoledronate and ibandronate to rats in an attempt to
determine the minimally nephrotoxic dose, defined as the
dose required to promote kidney injury.32 In this single-dose
study, 1 mg/kg of zoledronate as compared with 3 mg/kg of
ibandronate caused renal proximal tubular damage with loss
of brush border, cytoplasmic swelling, and cellular necrosis.
Distal tubular injury and necrosis occurred only in rats
treated with 10 mg/kg of zoledronate. The ratio between the
lowest lethal dose and the minimally nephrotoxic dose was 25
for ibandronate and 3.3 for zoledronate.
Human studies: case series and renal biopsy findings
Insights into the patterns and mechanisms of bisphosphonate
nephrotoxicity have been gained from case reports and short
series which highlight clinical and renal biopsy findings
(Figure 1). The first report described seven patients with
acute kidney injury (AKI) and nephrotic syndrome following
long-term treatment with pamidronate33 (Table 2). The
cohort consisted of five women and two men with a mean age
of 62.7 years. Six patients had MM and one had a history of
breast cancer. At the time of presentation and renal biopsy,
the mean serum creatinine was 3.6 mg/dl and the mean 24 h
urine protein was 12.4 g/day. All seven patients had received
monthly i.v. pamidronate for 15–48 months. Five of the seven
patients received doses of pamidronate that exceeded
recommended levels, including 360 mg/month in three
patients and 180 mg/month in two patients. Renal biopsy
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revealed collapsing FSGS associated with severe tubular
degenerative changes. Collapsing FSGS is a pattern of
glomerular disease that most commonly occurs in young,
African-American patients. The finding of collapsing FSGS in
a group of older Caucasian patients with a history of
malignancy was the initial observation that led to the
recognition of an association between pamidronate and this
pathologic lesion. Following discontinuation of pamidronate,
renal function improved in two of five patients.
Subsequent reports have reaffirmed the association of
pamidronate with nephrotic syndrome and a spectrum of
glomerular lesions ranging from collapsing FSGS to non-
collapsing forms of FSGS to minimal change disease.34–36
Barri et al.34 described five patients with MM who developed
nephrotic syndrome following treatment with pamidronate.
Three patients received a standard dose of 90 mg/month i.v.
for at least 1 year. The remaining two patients were part of an
experimental protocol whereby they received 50 mg contin-
uous infusion daily for 7 days every other week for 2 months
followed by a maintenance dose of 50 mg/month. Among the
five patients, the mean 24 h urine protein was 8.1 g/day and
the mean creatinine was 1.7 mg/100 ml. Renal biopsy revealed
minimal change disease in two patients, non-collapsing FSGS
in two patients, and a single patient with collapsing FSGS.
Following renal biopsy, pamidronate was discontinued. The
patient with collapsing FSGS progressed to ESRD, whereas
the two patients with minimal change disease had a remission
of proteinuria. Among the remaining two patients with
non-collapsing FSGS, one had persistent proteinuria with
normal renal function and the other had resolution of
proteinuria in the setting of worsening renal function.34
Desikan et al.35 described five patients with MM who
developed severe proteinuria (mean 13.5 g/day; range
2.96–25 g/day) following treatment with pamidronate at a
dose of 180 mg/month. Two of the five patients underwent
biopsy and were found to have FSGS. Although a single
patient became dialysis-dependent, the remaining four
patients had a marked reduction in proteinuria following
cessation or reduction in dose of pamidronate. The authors
of the study noted that none of 55 patients at their center
who had been treated with pamidronate at a dose of 90 mg/
month had developed progressive nephrotic proteinuria.35
Shreedhara et al.36 reported four patients with breast cancer
and one with MM who developed proteinuria and renal
insufficiency following treatment with pamidronate (90 mg/
month in four patients; 180 mg/month in the single
remaining patient). Three of the five patients underwent
renal biopsy and were found to have collapsing FSGS. In all
five patients, discontinuation of pamidronate led to sig-
nificant improvement in renal function and a decline in
proteinuria.
There has also been multiple individual case reports of
nephrotic syndrome associated with pamidronate.37–40 In one
report, a patient’s 24 h urine protein declined from 28.7 to
3.4 g/day after discontinuation of pamidronate.37 Due to life-
threatening thoracic and lumbar disease, pamidronate was
restarted and soon after, proteinuria increased to 6.4 g/day.
The authors of this report, who also described the initial
seven cases of pamidronate-associated collapsing FSGS,
noted that they had seen 10 additional cases since their
original report, bringing the total to 17 from a single referral
center.37 From these reports, it appears that pamidronate-
associated nephrotic syndrome mainly occurs in patients who
have MM and have received pamidronate at higher than
recommended doses. The most frequent pathologic lesion is
collapsing FSGS although less aggressive patterns of podocyte
injury, including minimal change disease and non-collapsing
FSGS, may be seen. In many cases, nephrotic syndrome
associated with pamidronate is at least partially reversible
following discontinuation of the offending agent.
Pamidronate also has been rarely associated with diseases
of the tubules and interstitium. Banerjee et al.42 described a
patient with hypercalcemia of unclear etiology who deve-
loped AKI, requiring dialysis after three 60 mg doses of
pamidronate administered over 2 weeks. Renal biopsy
a
b
Figure 1 | Renal biopsy findings in bisphosphonate
nephrotoxicity. (a) A glomerulus from a patient who had been
treated with pamidronate exhibits collapsing focal segmental
glomerulosclerosis with global wrinkling and retraction of the
glomerular basement membrane. There is global swelling and
proliferation of overlying visceral epithelial cells which contain
protein resorption droplets. (Jones methenamine silver,  400.)
(b) In this example of toxic acute tubular necrosis following
treatment with zoledronate proximal tubules exhibit severe
degenerative changes including luminal ectasia, cytoplasmic
simplification and hypereosinophilia, irregular luminal contours,
extensive loss of brush border, prominent nucleoli, and focal
apoptotic figures. (Hematoxylin and eosin,  400.)
1388 Kidney International (2008) 74, 1385–1393
r e v i e w MA Perazella and GS Markowitz: Bisphosphonate nephrotoxicity
revealed ATN and renal function subsequently recovered.
Similarly, Smetana et al.43 described a woman who was
treated with pamidronate 90 i.v. monthly for PMO and
developed progressive renal failure during the initial 20
months of therapy. Over that time period, the serum
creatinine increased from 1.1 to 2.7 mg/dl. Renal biopsy
revealed toxic ATN, pamidronate was discontinued, and her
serum creatinine declined over 4 months to 1.9 mg/dl.43
Buysschaert et al.44 reported a patient with hyperparathyr-
oidism who was treated with up to 360 mg/month of i.v.
pamidronate and developed a severe chronic tubulointer-
stitial nephropathy associated with Fanconi syndrome.
Following discontinuation of pamidronate, Fanconi syn-
drome resolved but there was minimal improvement in renal
function.
In contrast to pamidronate, zoledronate appears to be
mainly associated with injury to the tubules, resulting in a
toxic form of ATN. The initial report of toxic ATN following
treatment with zoledronate included four men and two
women with a mean age of 69.2 years.45 Five patients had a
history of MM and one had Paget’s disease. The mean
baseline serum creatinine was 1.4 mg/dl. Patients received
zoledronate at the recommended dose and infusion time
(4 mg/month i.v. over at least 15 min) and were found to
have AKI with a mean serum creatinine of 3.4 mg/dl and only
subnephrotic proteinuria following a mean of 4.7 months of
treatment (range 3–9 months). Renal biopsy revealed toxic
ATN, without evidence of collapsing FSGS. Discontinuation
of zoledronate led to improvement in renal function, with a
mean serum creatinine of 2.3 mg/dl at a mean of 3.2 months
following renal biopsy. Of note, only a single case of
nephrotic syndrome and collapsing FSGS following treatment
with zoledronate has been reported.41
It is important to note that the large trials which report
incidences of renal insufficiency following treatment with
pamidronate or zoledronate do not provide information on
proteinuria or mention renal biopsy findings. As a result, it
would be inaccurate to conclude that the patterns of
nephrotoxicity seen in case reports and clinical series are
entirely reflective of the patterns of nephrotoxicity seen in
large clinical trials. For instance, it is possible that
pamidronate is associated with ATN as often or even more
often than collapsing FSGS, but that the findings of
collapsing FSGS have gained attention due to the distinctive
clinical presentation of full nephrotic syndrome.
Human studies: nephrotoxicity observed in clinical trials and
government reporting systems
Malignant bone disease. Intravenous pamidronate is
recommended for use at a dose of 90 mg i.v. monthly infused
over 3 h for treatment of malignancy-associated bone disease.
A phase III trial that employed i.v. pamidronate 90–120 mg
i.v. monthly for 9 cycles in 203 patients with MM found no
adverse renal effects as compared with 189 placebo-treated
patients.46 A similar renal safety profile was noted at a similar
dose and schedule for treatment of patients with breast
cancer and osteolytic bone metastases.47 In this trial, 367
patients received i.v. pamidronate (90 mg) and 387 patients
received placebo. Serum and urine chemistries as well as
urinalysis were followed at regular intervals and no adverse
renal events were noted. A retrospective study examined
long-term renal safety of i.v. pamidronate (or pamidronate
Table 2 | Renal biopsy findings in bisphosphonate-associated nephrotic syndrome
Author/
reference
Patient
no.
Clinical
presentation Bisphosphonate
Renal biopsy
findings
Bisphosphonate
withdrawal?
Outcome following bisphosphonate
withdrawal
Markowitz33 1 NS/RI Pamidronate Collapsing FSGS No HD
2 NS/RI Pamidronate Collapsing FSGS Yes HD
3 NS/RI Pamidronate Collapsing FSGS No HD
4 NS/RI Pamidronate Collapsing FSGS Yes Increase in sCr
5 NS/RI Pamidronate Collapsing FSGS Yes Decline in sCr
6 NS/RI Pamidronate Collapsing FSGS Yes HD
7 NS/RI Pamidronate Collapsing FSGS Yes Decline in sCr
Barri34 1 NS Pamidronate MCD Yes Remission of NS
2 NS Pamidronate FSGS NOS Yes Persistent NS
3 NRP/RI Pamidronate MCD Yes Remission of NRP; decline in sCr
4 Proteinuria Pamidronate FSGS NOS Yes Decline in proteinuria; increase in sCr
5 NS/RI Pamidronate Collapsing FSGS Yes HD
Desikan35 1 NRP Pamidronate FSGS Yes Remission of proteinuria
2 NRP Pamidronate FSGS Yes Persistent NRP
Shreedhara36 1 NS/RI Pamidronate Collapsing FSGS Yes Remission of NS & RI
2 NS/RI Pamidronate Collapsing FSGS Yes Decline in proteinuria & sCr
3 NS/RI Pamidronate Collapsing FSGS Yes Decline in proteinuria & sCr
Markowitz37 1 NS Pamidronate Collapsing FSGS Yes Decline in proteinuria
Lockridge38 1 NS/RI Pamidronate MCD Yes HD
Kunin39 1 NS/RI Pamidronate Collapsing FSGS Yes HD
Nasr40 1 NS/RI Pamidronate Collapsing FSGS & MCN Yes Decline in proteinuria & sCr
Bodmer41 1 NS/RI Zoledronate Collapsing FSGS Yes HD
FSGS NOS, FSGS not otherwise specified; FSGS, focal segmental glomerulosclerosis; HD, hemodialysis; MCD, minimal change disease; MCN, myeloma cast nephropathy; NRP,
nephrotic range proteinuria; NS, nephrotic syndrome; RI, renal insufficiency; sCr, serum creatinine.
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before/after zoledronate) in 57 patients with various forms of
metastatic cancer (breast, 48; renal cell, 1; prostate, 1) or
MM8 over a median of 34 months of therapy.2 Patients who
had normal kidney function at baseline (median 0.89 mg/dl,
range 0.4–1.4 mg/dl) received pamidronate (90 mg every 3–4
weeks) or pamidronate/zoledronate (4 mg every 3–4 weeks).
Seven patients (12%) developed an increase in serum
creatinine concentration (40.5 mg/dl or doubling over
baseline). Six patients continued on therapy with two
improving and four having no further rise in serum
creatinine, whereas treatment was discontinued in one
patient. Thus, i.v. pamidronate does maintain some ne-
phrotoxic risk.
In contrast to pamidronate, renal safety concerns were
noted with i.v. zoledronate in two phase III oncology trials
involving patients with breast, lung, and other cancers with
bone metastases that used doses of 4 and 8 mg i.v. infused
over 5 min every 3–4 weeks.17,48 In a phase III trial comparing
zoledronate to pamidronate that enrolled 1648 patients with
MM or advanced breast cancer, two protocol adjustments
were required to reduce the incidence of renal insufficiency
with zoledronate to a rate similar to that seen with
pamidronate. Initially, patients were treated with zoledronate
8 mg i.v. infused over 5 min. The first protocol change
increased the infusion time from 5 to 15 min, whereas the
second reduced the dose from 8 to 4 mg.17 Following the two
protocol adjustments, the incidence of nephrotoxicity,
defined as an increase in serum creatinine of at least
0.5 mg/dl, was 9.3% with zoledronate as compared to 8.1%
for pamidronate. It should be noted that although these
percentages may appear alarmingly high, this study did not
include a placebo group; AKI may occur from a variety of
etiologies and with some frequency in patients with myeloma
or metastatic carcinoma. Another trial in patients with bone
metastases from various malignancies noted a statistically
insignificant difference in the incidence of abnormal kidney
function between zoledronate (10.9%) and a placebo group
(6.7%).48 Importantly, this study included only patients with
lung cancer and other solid tumors (except breast and
prostate cancer) and did not include patients with MM.
In 2003, the Food and Drug Administration Adverse Event
Reporting System reported 72 cases of renal failure associated
with i.v. zoledronate identified over an 18-month period.49
The 72 patients had a mean age of 71 years. Indications for
zoledronate included MM and solid organ malignancies in 42
and 22 patients, respectively. The mean baseline serum
creatinine was 1.7 mg/dl, which increased to a mean of
6.5 mg/dl with zoledronate treatment and decreased to a
mean of 2.7 mg/dl following drug discontinuation. Renal
failure was noted an average of 56 days after commencing
therapy, following a mean of 2.4 i.v. doses. Risk factors for
nephrotoxicity were advanced cancer, previous bisphospho-
nate exposure (mainly pamidronate), and exposure to
nonsteroidal anti-inflammatory drugs. Most patients were
left with chronic kidney disease, 27 patients required renal
replacement therapy, and 18 patients expired. The French
Adverse Effect Reporting Database similarly noted renal
toxicity associated with i.v. zoledronate utilized to treat
cancer.50 They identified seven patients who developed AKI
(four de novo; three superimposed on chronic kidney
disease). Clinical follow-up after discontinuation of zoledro-
nate was available for six patients, including three that
completely recovered and three who were left with permanent
renal impairment. Risk factors for renal failure were similar
to those previously noted. Further evidence of increased
nephrotoxicity associated with i.v. zoledronate (median
treatment 9.8 months) was demonstrated in a retrospective
study of 122 patients with metastatic prostate cancer followed
over a median of 11.7 months.51 In this study, the median
patient age was 70 years, 59% of patients had hypertension,
and 91% of patients had a baseline serum creatinine
o1.4 mg/dl. Using standard definitions of renal toxicity,
23.8% of patients developed nephrotoxicity based on
increased serum creatinine concentration and 41.8% based
on a decline in CrCl. Renal toxicity increased with duration
of therapy using either serum creatinine increases
(o6 month, 11.1%; 412 months, 21.8%; 424 months,
26.3%) or declines in CrCl (o6 month, 23.9%; 412 months,
45.5%; 424 months, 36.8%) as well as with prior
pamidronate therapy (increase in serum creatinine 45.5 vs
19%, decrease in CrCl 72.7 vs 35%) and older age.
The American Society of Clinical Oncology 2007 Clinical
Practice Guideline Update recommends that pamidronate
(90 mg over no less than 2 h) and zoledronate (4 mg over
15 min) be employed for patients with normal kidney
function.4 In patients with mild-to-moderate kidney disease
(estimated CrCl 30–60 cc/min), the dose of zoledronate
should be reduced with no change in pamidronate, although
the committee suggests that clinicians ‘consider reducing the
initial dose of pamidronate’ (Table 1). For more severe
kidney disease (estimated CrCl o30 cc/min), zoledronate is
not recommended whereas the infusion time for pamidro-
nate should be increased to 4–6 h, again with a consideration
for reducing the dose. Serum creatinine should be monitored
before each dose of bisphosphonate and the drug withheld in
patients who develop an otherwise unexplained increase in
serum creatinine concentration. The drug can be restarted if
the serum creatinine returns to within 10% of baseline. Also,
the development of albuminuria (confirmed by 24 h urine
collection) should be monitored for at 3–6 month intervals,
with a similar drug withhold if unexplained albuminuria
develops.
Ibandronate appears to have less nephrotoxic potential
than other available i.v. bisphosphonates. In 25 patients with
metastatic prostate cancer, severe bone pain, and a creatinine
o2.5 mg/dl, ibandronate infused at a dose of 6 mg i.v. over
1 h for 3 consecutive days followed by a single 6 mg infusion
every 4 weeks was not associated with nephrotoxicity over an
undefined period of follow-up.52 In another study, both 2 mg
and 6 mg i.v. ibandronate doses infused over 1–2 h every 3–4
weeks for metastatic breast cancer did not cause renal
toxicity.53 In this study, 158 patients received placebo,
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whereas 154 patients received 2 mg and 154 patients received
6 mg doses. The percentage of patients with increased serum
creatinine concentrations was similar between all groups. A
post hoc analysis of a trial in 309 patients with breast cancer
treated with either i.v. ibandronate (n¼ 152) or placebo
(n¼ 157) also showed similar adverse renal effects in both
groups (ibandronate 6%; placebo 12%) over 2 years of
follow-up.54 In this study, a renal event was defined as
increase in serum creatinine concentration of 0.5 mg/dl in
patients with a baseline serum creatinine o1.4 mg/dl and
1.0 mg/dl if baseline serum creatinine was 41.4 mg/dl.
Finally, a short-term study in 18 patients with advanced
metastatic cancer employing ibandronate 4 mg infused over
2 h on 4 consecutive days was not associated with
nephrotoxicity.55
The renal safety of ibandronate has also been examined in
patients with underlying kidney disease. In an open-label
study, i.v. ibandronate (6 mg over 30 min) was administered
to 21 MM patients with baseline renal insufficiency (CrCl
8–120 cc/min, 17 of 21 with underlying kidney disease) and
the short-term renal effects were measured.56 No changes in
serum creatinine or urinary markers of tubular injury were
noted. Seven MM patients with AKI due to hypercalcemia/
nephrocalcinosis received i.v. ibandronate (6 mg over 30 min
in 6 patients, 2 mg in 1 patient followed by 4 or 6 mg every
3–4 weeks) and were followed for correction of serum
calcium concentration and renal function parameters.57
Hypercalcemia was corrected and renal function improved
or normalized in all patients. In contrast to pamidronate and
zoledronate, currently published clinical studies suggest that
IV ibandronate does not exhibit significant nephrotoxicity
and is well tolerated, even in patients with underlying kidney
disease.
Postmenopausal osteoporosis. Treatment of PMO with i.v.
bisphosphonates requires lower doses and longer dosing
intervals which, not surprisingly, results in less nephrotoxi-
city. The limited data on oral pamidronate (4.8–6.0 mg/kg
daily) for osteoporosis reflect a safe renal profile.58 Similarly,
i.v. pamidronate for PMO is understudied but appears to
have a relatively safe renal profile at doses that range from
30 mg every 3 months up to 60 mg monthly.18,19
Three large studies have examined the efficacy and safety
of i.v. zoledronate in the treatment of PMO or as an agent to
reduce mortality in patients who have had a recent hip
fracture. In a 12-month study of 351 women with PMO who
received zoledronate 4 mg i.v. annually in single or divided
doses, no adverse effects on renal function were reported.21 A
subsequent double-blind, placebo-controlled trial enrolled
7765 women with PMO who were administered zoledronate
4 mg i.v. or placebo once per year.24 In this 3-year follow-up
study, a transient decline in renal function (increase in serum
creatinine concentration 40.5 mg/dl) occurred more fre-
quently in the i.v. zoledronate group (1.3% vs 0.4%;
P¼ 0.001). However, renal function was not significantly
different between the two groups at the end of 3 years. A
third study examined the efficacy of zoledronate 5 mg i.v.
once per year to reduce the incidence of new fractures among
patients with a recent hip fracture. This double-blind,
placebo-controlled trial enrolled 2127 patients. An increase
in serum creatinine of 40.5 mg/dl was seen in a similar
percentage of patients in both groups (6.2% in zoledronate
group vs 5.6% in placebo group; P¼ 0.62).25 Of note, the
efficacy of zoledronate as a treatment for PMO or to reduce
postfracture mortality was well established in each of the
three studies.
Ibandronate administered at a dose of 2 mg i.v. every
2 months or 3 mg i.v. every 3 months has been compared to
daily oral ibandronate in a study of 1395 women with
PMO.59 In this 2-year randomized, double-blind, noninfer-
iority study, both i.v. ibandronate dosing schedules were as
effective as oral ibandronate. No cases of AKI, defined as
either an increase in serum creatinine concentration of
40.5 mg/dl (baseline creatinine o1.4 mg/dl) or 1.0 mg/dl
(baseline creatinine 41.4 mg/dl) or twofold increase in
serum creatinine during treatment, were reported. In more
than 3000 patients with PMO treated with i.v. ibandronate
(2–12 mg annually), pooled safety data demonstrate a safe
renal profile with no adverse renal effects or cases of renal
failure.60 In this analysis, the mean decline in estimated
glomerular filtration rate in patients exposed to 12 mg of i.v.
ibandronate (0.72 ml/min) was similar to patients treated
with 2.5 mg of oral ibandronate (0.28 ml/min) and placebo
(0.91 ml/min).
Mechanism of nephrotoxicity
Although the mechanism(s) by which bisphosphonates are
associated with nephrotoxicity are not well understood,
inferences can be drawn from the pathologic findings.
Collapsing FSGS is the most severe histologic variant of
FSGS61 and results from direct podocyte injury, whereby
visceral epithelial cells leave their terminally differentiated state,
enter the cell cycle, lose expression of markers of differentia-
tion, and exhibit an immature phenotype.62 In the initial
report of seven cases of pamidronate-associated collapsing
FSGS, similar alterations were seen, including loss of podocyte
synaptopodin and increased expression of proliferation marker
Ki-67, in both podocytes and tubular epithelia.33 Based on the
pathologic findings, pamidronate toxicity appears to target
podocytes and possibly tubular epithelium.
Toxic ATN, the main pattern of renal injury seen in
patients treated with zoledronate, is characterized by toxicity
directed at tubular epithelium, as evidenced by the increased
tubular expression of Ki-67 and diminished and altered
expression of tubular Naþ , Kþ -ATPase. The concept that
zoledronate toxicity targets tubular epithelia whereas pami-
dronate targets visceral epithelial cells and possibly tubular
epithelia is likely to be an oversimplication in that rare cases
of pamidronate-associated toxic ATN and a single case of
zoledronate-associated collapsing FSGS have been reported.
Furthermore, renal biopsy findings are not provided in any of
the large trials that have documented renal insufficiency
following treatment with pamidronate or zoledronate.
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Bisphosphonate nephrotoxicity may result from similar
mechanisms to that in which these agents exert their
therapeutic effects in osteoclasts. Inhibition of the mevalo-
nate pathway within the osteoclast is thought to be an
important mechanism of action of bisphosphonates, leading
to alterations in integrin signaling, endosomal trafficking,
and membrane ruffling, as well as induction of apoptosis.7–11
Nitrogen-containing bisphosphonates exert this effect on
osteoclasts by direct inhibition of farnesyl diphosphate
synthase, an enzyme present in the mevalonate pathway.
Recent experiments have shown that zoledronate and
ibandronate inhibit farnesyl diphosphate in a human
proximal tubular cell line, and that this step may be followed
by decreased levels of prenylated proteins and later
cytotoxicity, an observation that strongly supports the
concept that the therapeutic effect of bisphosphonates on
osteoclasts may have an identical mechanism to the toxic
effect on the kidney.63 Bisphosphonates also impair cellular
energetic and disrupt cytoskeleton assembly within osteo-
clasts.12,13 Bisphosphonates may exert similar effects in
tubular and visceral epithelial cells, thereby producing toxic
ATN and collapsing FSGS, respectively. This concept is
supported by the high renal exposure to bisphosphonates and
the finding that bisphosphonates can induce apoptosis in
other cell types including cancerous cells.64 Furthermore,
podocytes, much like osteoclasts, have a highly complex
cytoskeleton and disruption of this cytoskeleton plays a role
in the development of collapsing FSGS. A recent case report
raises the possibility that in some cases, pamidronate-
associated FSGS may result from drug-induced mitochon-
drial toxicity targeting visceral epithelial cells and tubular
epithelia.65
It is unclear as to why ibandronate has a safer renal profile
than the alternative i.v. bisphosphonates, although this
finding clearly argues against a class effect. The difference
in nephrotoxic potential may relate to two pharmacokinetic
differences. Compared to pamidronate and zoledronate,
ibandronate is more highly protein bound (87% vs 54 and
56%), which may limit renal exposure to free drug.16 Second,
the renal tissue half life of ibandronate is much shorter than
zoledronate,16 possibly allowing for more time for injured
cells to undergo repair between repeat dosing.
CONCLUSION
Intravenous bisphosphonates are highly effective agents for
the treatment of osteoporosis, hypercalcemia of malignancy,
and osteolytic bone metastases. Nephrotoxicity is an
important potential limiting factor in the use of these agents,
in particular pamidronate and zoledronate. Bisphosphonate
nephrotoxicity is dose-dependent and infusion time-depen-
dent, and can be limited by increasing the time interval
between doses. The two main i.v. bisphosphonates in use for
these indications in the United States are zoledronate and
pamidronate. Patterns of nephrotoxicity seen with these
agents include toxic ATN and collapsing FSGS. With both of
these agents, severe nephrotoxicity can often be avoided by
strict adherence to guideline for monitoring serum creatinine
prior to each treatment, withholding therapy in the setting of
renal insufficiency, and adjusting doses in the setting of pre-
existing chronic kidney disease. Currently, ibandronate is
approved in the US for treatment of PMO and in Europe for
treatment of PMO and complications of cancer. In contrast
to pamidronate and zoledronate, ibandronate appears to
have a safer renal profile with no evidence of nephrotoxicity,
even in patients with abnormal baseline kidney function.
Future studies and accumulated clinical experience are
needed to better determine whether ibandronate is an agent
with any significant nephrotoxicity.
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